EP1666041A3 - Derivés de la xanthine contre désordres neurodégénératifs - Google Patents

Derivés de la xanthine contre désordres neurodégénératifs Download PDF

Info

Publication number
EP1666041A3
EP1666041A3 EP06005220A EP06005220A EP1666041A3 EP 1666041 A3 EP1666041 A3 EP 1666041A3 EP 06005220 A EP06005220 A EP 06005220A EP 06005220 A EP06005220 A EP 06005220A EP 1666041 A3 EP1666041 A3 EP 1666041A3
Authority
EP
European Patent Office
Prior art keywords
neurodegenerative disorders
treating neurodegenerative
xanthine derivatives
xanthine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06005220A
Other languages
German (de)
English (en)
Other versions
EP1666041A2 (fr
Inventor
Junichi Pastorale Heim Shimada
Masako Kurokawa
Ken Ikeda
Fumio Susuki
Yoshihisa Kuwana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of EP1666041A2 publication Critical patent/EP1666041A2/fr
Publication of EP1666041A3 publication Critical patent/EP1666041A3/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
EP06005220A 1997-09-05 1998-09-04 Derivés de la xanthine contre désordres neurodégénératifs Withdrawn EP1666041A3 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24056597 1997-09-05
EP98941725A EP1016407B1 (fr) 1997-09-05 1998-09-04 Derives de la xanthine contre l'ischemie cerebrale

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP98941725A Division EP1016407B1 (fr) 1997-09-05 1998-09-04 Derives de la xanthine contre l'ischemie cerebrale

Publications (2)

Publication Number Publication Date
EP1666041A2 EP1666041A2 (fr) 2006-06-07
EP1666041A3 true EP1666041A3 (fr) 2008-04-02

Family

ID=17061422

Family Applications (2)

Application Number Title Priority Date Filing Date
EP98941725A Expired - Lifetime EP1016407B1 (fr) 1997-09-05 1998-09-04 Derives de la xanthine contre l'ischemie cerebrale
EP06005220A Withdrawn EP1666041A3 (fr) 1997-09-05 1998-09-04 Derivés de la xanthine contre désordres neurodégénératifs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP98941725A Expired - Lifetime EP1016407B1 (fr) 1997-09-05 1998-09-04 Derives de la xanthine contre l'ischemie cerebrale

Country Status (8)

Country Link
US (4) US6727259B2 (fr)
EP (2) EP1016407B1 (fr)
JP (1) JP2009102334A (fr)
AT (1) ATE325610T1 (fr)
AU (1) AU734138B2 (fr)
DE (1) DE69834500T2 (fr)
ES (1) ES2264210T3 (fr)
WO (1) WO1999012546A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2686123T3 (es) 2002-01-28 2018-10-16 Kyowa Hakko Kogyo Co., Ltd Antagonistas del receptor A2A para su uso en el tratamiento de trastornos del movimiento
AR039385A1 (es) 2002-04-19 2005-02-16 Astrazeneca Ab Derivados de tioxantina como inhibidores de la mieloperoxidasa
AR056615A1 (es) * 2002-12-27 2007-10-17 Kyowa Hakko Kogyo Kk Un metodo de tratamiento de trastornos de la conducta
EP1631294B1 (fr) 2003-06-10 2010-09-15 Kyowa Hakko Kirin Co., Ltd. Methode de traitement d'un trouble de l'anxiete
TW200507850A (en) 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
JPWO2005053695A1 (ja) * 2003-12-04 2007-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 多発性硬化症予防剤または治療剤
AU2004296137A1 (en) * 2003-12-09 2005-06-23 Kyowa Hakko Kirin Co., Ltd. Preventive and/or therapeutic agent for higher brain dysfunction
US7763625B2 (en) * 2004-01-28 2010-07-27 Kyowa Hakko Kirin Co., Ltd. Agents for treating migraine
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
TW200806667A (en) * 2006-04-13 2008-02-01 Astrazeneca Ab New compounds
TW200804383A (en) 2006-06-05 2008-01-16 Astrazeneca Ab New compounds
US20090054468A1 (en) * 2007-08-23 2009-02-26 Astrazeneca Ab New Use 938
CN102438624B (zh) * 2009-03-13 2016-03-30 阿德维纳斯治疗私人有限公司 取代的稠合嘧啶化合物
UA113383C2 (xx) 2009-09-02 2017-01-25 Терапевтичний агент для лікування тривожних розладів
UA110097C2 (uk) 2009-09-02 2015-11-25 Терапевтичний агент для лікування розладів настрою
AU2013251079B2 (en) * 2012-04-20 2017-03-23 Ucb Pharma S.A. Methods for treating Parkinson's disease
JO3544B1 (ar) 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd عامل علاجي للاختلال الوظيفي في الفص الجبهي

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243192A2 (fr) * 1986-04-25 1987-10-28 The Wellcome Foundation Limited Antivirus 8-phénylxanthines
EP0374808A2 (fr) * 1988-12-22 1990-06-27 Boehringer Ingelheim Kg Dérivés de xanthine à activité antagoniste d'adénosine
EP0389282A2 (fr) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Dérivés de xanthine, procédé pour leur préparation et leur utilisation médicinale
US5173491A (en) * 1990-08-10 1992-12-22 Adir Et Compagnie Pharmaceutical compositions and a method for the treatment of memory disorders, intellectual disorders of ageing and alzheimer's disease
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
EP0590919A1 (fr) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Agents thérapeutiques pour la maladie de Parkinson
WO1994009787A1 (fr) * 1992-10-28 1994-05-11 Boehringer Ingelheim Kg Combinaison synergique pour le traitement de maladies degeneratives liees au vieillissement, contenant un antagoniste de l'adenosine et un cholinomimetique
EP0607607A1 (fr) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Dérivés de la xanthine
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
WO1995011681A1 (fr) * 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
WO1995013075A1 (fr) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
EP0698607A1 (fr) * 1994-02-23 1996-02-28 Kyowa Hakko Kogyo Kabushiki Kaisha Derive de la xanthine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3641010A (en) 1970-06-11 1972-02-08 Parke Davis & Co Novel xanthine compounds and means for obtaining the same
US4772607A (en) 1986-05-20 1988-09-20 Warner-Lambert Company Dialkenyl derivatives of xanthine, pharmaceutical compositions and methods of use therefor
EP0559893B1 (fr) 1990-10-18 1999-02-03 Kyowa Hakko Kogyo Co., Ltd. Derive de xanthine
US5484920A (en) 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2093403C (fr) * 1992-04-08 1999-08-10 Fumio Suzuki Agent de traitement de la maladie de parkinson
CA2116967C (fr) 1992-07-08 2003-08-19 Fumio Suzuki Antidepresseurs
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
JP3165769B2 (ja) * 1992-12-24 2001-05-14 協和醗酵工業株式会社 キサンチン誘導体
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
AU711535B2 (en) 1994-02-23 1999-10-14 Kyowa Hakko Kirin Co., Ltd. Platelet growth accelerator
JPH0940652A (ja) * 1995-07-28 1997-02-10 Kyowa Hakko Kogyo Co Ltd ウラシル誘導体の製造方法

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243192A2 (fr) * 1986-04-25 1987-10-28 The Wellcome Foundation Limited Antivirus 8-phénylxanthines
EP0374808A2 (fr) * 1988-12-22 1990-06-27 Boehringer Ingelheim Kg Dérivés de xanthine à activité antagoniste d'adénosine
EP0389282A2 (fr) * 1989-03-23 1990-09-26 BEECHAM - WUELFING GmbH & Co. KG Dérivés de xanthine, procédé pour leur préparation et leur utilisation médicinale
US5173491A (en) * 1990-08-10 1992-12-22 Adir Et Compagnie Pharmaceutical compositions and a method for the treatment of memory disorders, intellectual disorders of ageing and alzheimer's disease
DE4307883A1 (en) * 1992-03-12 1993-09-23 Westarp Martin Egon Dr Med Use of anti-retroviral substances - to treat motor-neuronal diseases
EP0590919A1 (fr) * 1992-09-28 1994-04-06 Kyowa Hakko Kogyo Co., Ltd. Agents thérapeutiques pour la maladie de Parkinson
WO1994009787A1 (fr) * 1992-10-28 1994-05-11 Boehringer Ingelheim Kg Combinaison synergique pour le traitement de maladies degeneratives liees au vieillissement, contenant un antagoniste de l'adenosine et un cholinomimetique
EP0607607A1 (fr) * 1992-12-24 1994-07-27 Kyowa Hakko Kogyo Co., Ltd. Dérivés de la xanthine
WO1994025462A1 (fr) * 1993-05-03 1994-11-10 The United States Of America, Represented By The Derives de 1,3,7-trialkyl-xanthine substitues en position 8 utiles comme antagonistes de recepteurs d'adenosine a2 a selectivite
WO1995011681A1 (fr) * 1993-10-29 1995-05-04 Merck & Co., Inc. Antagonistes du recepteur de l'adenosine humaine
WO1995013075A1 (fr) * 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
EP0698607A1 (fr) * 1994-02-23 1996-02-28 Kyowa Hakko Kogyo Kabushiki Kaisha Derive de la xanthine

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALVAREZ X A ET AL: "S9977-2 REDUCES LEARNING IMPAIRMENT AND BRAIN INTERLEUKIN-1ÄBETAÜ OVERPRODUCTION IN RATS WITH NEUROTOXIC LESIONS IN THE NUCLEUS BASALIS OF MEYNERT", EUROPEAN NEUROPSYCHOPHARMACOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, AMSTERDAM, NL, vol. 3, no. 3, 1993, pages 425 - 426, XP008080012, ISSN: 0924-977X *
CACABELOS R: "Clinical neurosciences and Alzheimer's disease", CLINICAL SCIENCE 1996 UNITED KINGDOM, vol. 90, no. 3, 1996, pages 153 - 156, XP008080020, ISSN: 0143-5221 *
FIEBICH B L ET AL: "ADENOSINE A(2B) RECEPTORS MEDIATE AN INCREASE IN INTERLEUKIN (IL)-6 MRNA AND IL-6 PROTEIN SYNTHESIS IN HUMAN ASTROGLIOMA CELLS", JOURNAL OF NEUROCHEMISTRY, NEW YORK, NY, US, vol. 66, no. 4, April 1996 (1996-04-01), pages 1426 - 1431, XP008079987, ISSN: 0022-3042 *
HEESE K ET AL: "Nerve growth factor (NGF) expression in rat microglia is induced by adenosine A2a-receptors.", NEUROSCIENCE LETTERS. IRELAND 8 AUG 1997, vol. 231, no. 2, 8 August 1997 (1997-08-08), pages 83 - 86, XP002205285, ISSN: 0304-3940 *
WILLIAMS M ET AL: "ALZHEIMER'S DISEASE AND RELATED DEMENTIAS: PROSPECTS FOR TREATMENT", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, vol. 6, no. 6, June 1997 (1997-06-01), pages 735 - 757, XP008080011, ISSN: 1354-3784 *

Also Published As

Publication number Publication date
EP1016407A4 (fr) 2003-01-02
ATE325610T1 (de) 2006-06-15
US20040229888A1 (en) 2004-11-18
US7115614B2 (en) 2006-10-03
AU734138B2 (en) 2001-06-07
WO1999012546A1 (fr) 1999-03-18
DE69834500T2 (de) 2007-05-03
EP1016407A1 (fr) 2000-07-05
AU8997698A (en) 1999-03-29
EP1016407B1 (fr) 2006-05-10
US20080207649A1 (en) 2008-08-28
US20030158214A1 (en) 2003-08-21
JP2009102334A (ja) 2009-05-14
US6727259B2 (en) 2004-04-27
DE69834500D1 (de) 2006-06-14
EP1666041A2 (fr) 2006-06-07
US20060258688A1 (en) 2006-11-16
ES2264210T3 (es) 2006-12-16

Similar Documents

Publication Publication Date Title
EP1666041A3 (fr) Derivés de la xanthine contre désordres neurodégénératifs
EP2201944A3 (fr) Utilisation de 2-aminoacétamides substitués pour le traitement, la prévention ou l'amélioration de la maniaco-dépression
EP1659111A3 (fr) Derives de piperidine utiles comme des antagonistes de ccr5
ZA95631B (en) Prolineamide derivatives
EP1797878A3 (fr) Dérivés de benzothiazoles
IL127244A (en) Substituted amines, methods of their preparation and pharmaceutical compositions containing them
CA2356380A1 (fr) Effets immunosuppresseurs de derives de la pteridine
EP0748817A3 (fr) Dérivés de l'hormone parathyrodienne et leur utilisation
WO2003048164A3 (fr) Antagonistes du recepteur a2a de l'adenosine
CA2455539A1 (fr) Promoteurs de la croissance chez le porc et procede pour promouvoir la croissance chez le porc
CA2233315A1 (fr) Compositions pharmaceutiques contenant des derives d'acide hydroximique
AU6518998A (en) Morphinane derivatives and medicinal use thereof
CA2234247A1 (fr) Derive carbostyrylique pour le traitement de maladies oculaires
WO1992019211A3 (fr) Imidazobenzoquinones et composition contenant ces dernieres permettant de prevenir ou de traiter l'hypertension ou l'insuffisance cardiaque
CA2263353A1 (fr) Derives d'arylsulfonylimidazoline agissant en tant qu'agents anti-tumoraux
EP0412940A3 (en) Hydantoin or imidazolidinetrione derivatives for the prevention or treatment of renal failure
GR3025568T3 (en) Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia.
EP1026162A4 (fr) Agent anti-rhumatismal
YU31995A (sh) Benzotiofeni glikopiranozida, postupak za njihovo dobijanje i njihova farmaceutska formulacija
WO1999005103A3 (fr) Derives d'amidino-camptothecine
EP1062948A4 (fr) Medicaments contre les troubles diastoliques cardiaques
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
ES2196174T3 (es) `derivados de sesquiterpeno de actividad antiviral.
PL352119A1 (en) Derivatives of aminotetraline for treatment of cardiovascular diseases
CA2299909A1 (fr) Agent therapeutique pour troubles neurodegeneratifs

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060331

AC Divisional application: reference to earlier application

Ref document number: 1016407

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KUWANA, YOSHIHISA

Inventor name: SUSUKI, FUMIO

Inventor name: IKEDA, KEN

Inventor name: KUROKAWA, MASAKO

Inventor name: SHIMADA, JUNICHIPASTORALE HEIM

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 9/10 20060101ALI20070917BHEP

Ipc: A61K 31/52 20060101AFI20060425BHEP

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

AKX Designation fees paid

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20081117

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: KYOWA HAKKO KIRIN CO., LTD.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090528